Price$4.68+0.18 (+4.00%)
01:45 PM07:45 PM
News · 26 weeks54+14%
2026-01-182026-07-12
Mix2690d
- Other15(58%)
- SEC Filings10(38%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee OsteoarthritisFDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face declined quality-of-life and limited treatment options.RMAT designation provides the benefit of intensive, early FDA engagement and guidance for efficient drug development including potential eligibility for accelerated approval, priority review and other opportunities to expedite review and approval. Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced that the U.S. Food and Drug Administrati
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026Nes-Ziona, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced a 1-for-15 reverse split (the "Reverse Split") of its ordinary shares. Beginning on July 9, 2026, the Company’s ordinary shares will trade on The Nasdaq Capital Market on a split-adjusted basis. As a result of the Reverse Stock Split, every fifteen ordinary shares will automatically be combined into one ordinary share. Upon effectiveness of the Reverse Split, the number of authorized ordinary shares will be ratably reduced from 2,375,000,000 to 158,333,334, and the par value of each ordinary share will ratably increase from NIS 0.40 to
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading VolumeRanked second globally in 24-hour spot trading volume, Gate further extends market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, June 24, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company"), "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced that its primary treasury asset, the RAIN token, is expected to be listed on the Gate cryptocurrency exchange, effective June 24, 2026 at 10:00 AM UTC. The listing represents a continued expansion of RAIN’s exchange infrastructure, increasing its accessibility, global reach, and token liquidity.According to Gate
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 BillionAs of June 18, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion1. Nes-Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, ", Enlivex", or the ", Company", )), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of June 20, 2026, the Company held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion1. The Company's treasury metrics, as reflected on its public market data dashboard, indicate a Treasury NAV per Share of $4.671 as of June 20, 2026, based on current RAIN token holdings relative to total number of the Company’
- PREnlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with OsteoarthritisNes-Ziona, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the issuance of an Australian patent, numbered 2020340629, titled, "THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS". The patent will provide Enlivex with added intellectual property protection in Australia through at least 2040 with claims covering methods of using Allocetra™ to treat subjects with osteoarthritis. With this issuance, the Company has secured patent protection for Allocetra™ in osteoarthritis in an additional major jurisdiction, further strengthening its global intellec
- PRENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026As a Gold Sponsor of the Paris event, Enlivex will host a curated dinner today for leading institutional asset managers, allocators, and digital asset investors Nes-Ziona, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, ", Enlivex", or the ", Company", )), a quality longevity company powered by a prediction markets treasury, today announced that it is a Gold Sponsor of Proof of Talk 2026, taking place June 2-3, 2026, at the Louvre Palace and Musée des Arts Décoratifs in Paris. Proof of Talk is one of Europe's leading institutional summits on digital assets, convening approximately 2,500 senior decision-makers across asset management, banking, policy, and Web3, with a
- PRAllocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026The data were selected for an oral podium presentation at EULAR and will be presented by Prof. Philip Conaghan, a globally recognized key opinion leader in osteoarthritis Nes-Ziona, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, ", Enlivex", or the ", Company", )), a quality longevity company powered by a prediction markets treasury, today announced that it will present at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology, taking place June 3-7, 2026, in London, UK. The presentation will feature extended 3-month and 6-months clinical data, as well as comprehensive mechanistic and pharmacological characterization data,
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory BoardAs of May 27, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.16 billion.Separately, the Rain Foundation recently announced the appointment of five industry leaders to its advisory board, supporting the next phase of growth of the Rain protocol, the primary digital asset in Enlivex's prediction markets treasury strategy. Nes-Ziona, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, ", Enlivex", or the "Company", )), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of May 27, 2026, the Company held 79,568,550,005 RAIN tokens with a total value of approximately
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional LiquidityRain, with an additional $100 Million Liquidity Commitment, Currently Anchors Top Three Positioning Among Global Prediction Market Leaders, Following Polymarket, with Approximately $450 million, and Kalshi1.Rain's Upgraded Positioning as a Top-3 Prediction Market and the Scale of its Capital Deployment Reinforce the Potential of the Enlivex Treasury StrategyAs of May 26, 2026, Enlivex's RAIN token holdings were 79,568,550,005 tokens, with a total value of approximately $919 million. In addition, Enlivex holds an option to acquire up to 271,372,418,179 RAIN tokens from the Rain Foundation, at a purchase price of $0.0033 per RAIN token. The option's expiration date is Dec. 31, 2027. The option
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee OsteoarthritisEnrollment milestone follows FDA IND clearance received in March 2026 and Danish Medicines Agency (DKMA) approval received in April 2026 Nes-Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the dosing of the first patient at a United States clinical site in the Phase 2b clinical trial of Allocetra™ for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA). The global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial is designed to evaluate the efficacy and safety
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Announces Receipt of Nasdaq Minimum Bid Price NotificationNes-Ziona, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company")), a quality longevity company powered by a prediction markets treasury, today announced that it has received a notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq"), stating that the closing bid price of the Company's ordinary shares during the 30 consecutive business days prior to the date of the Notice did not meet the $1.00 minimum bid price requirement in accordance with Nasdaq Listing Rule 5550(a)(2). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided with an initial period of 180 calendar days, or until November 9, 2026, to regain complia
- SECSEC Form 424B3 filed by Enlivex Ltd.424B3 - Enlivex Ltd. (0001596812) (Filer)
- PREnlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency ExchangeThe listing on one of the world's largest global cryptocurrency exchanges expands market access and secondary liquidity for Enlivex's primary digital treasury asset Nes-Ziona, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company")), a quality longevity company powered by a prediction markets treasury, today reported that its treasury asset, the RAIN token, has been listed on the HTX cryptocurrency exchange, effective April 29, 2026. The listing marks an important step forward for RAIN, significantly increasing its accessibility, global reach, and token liquidity. HTX (formerly Huobi) is a leading global cryptocurrency exchange serving over 160 c
- PREnlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 MillionNew acquisitions from Rain Foundation underlines Enlivex's disciplined prediction markets treasury strategy Nes-Ziona, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company")), a quality longevity company powered by a prediction markets treasury, today announced that as of April 27, 2026, Enlivex's total RAIN holdings increased to 78,819,756,062 tokens, which had a total value of $567 million1. Oren Hershkovitz, Ph.D, CEO of Enlivex, said, "Securing additional RAIN at a material discount to recent market prices reflects our disciplined treasury strategy that we believe may potentially create additional shareholder value. Our approach is supporte
- PREnlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World CongressNes-Ziona, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company")), a quality longevity company powered by a prediction markets treasury, today announced that it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI) 2026 World Congress on Osteoarthritis, taking place April 23-26, 2026, in West Palm Beach, Florida, USA. The presentations will feature 3-month and 6-month endpoints clinical data from the Phase IIa (NCT06233474) for Allocetra™ in patients with moderate-to-severe knee osteoarthritis (KOA). The Phase IIa data demonstrated clinically meaningful and statistically significant improvement of the Al
- SECSEC Form F-3 filed by Enlivex Ltd.F-3 - Enlivex Ltd. (0001596812) (Filer)
- SECSEC Form 6-K filed by Enlivex Ltd.6-K - Enlivex Ltd. (0001596812) (Filer)
ENLV FAQ
6 questionsWhat does Enlivex Ltd. do?
Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are...Where does ENLV stock trade?
Enlivex Ltd. (ENLV) is listed on NASDAQ.What sector and industry is ENLV in?
Enlivex Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Enlivex Ltd. go public?
Enlivex Ltd. (ENLV) completed its IPO in 2014.What companies are similar to ENLV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ENLV side-by-side with any of them on Quantisnow.How can I track ENLV on Quantisnow?
Quantisnow aggregates Enlivex Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ENLV to receive live email and push alerts on every new disclosure.